Mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning: a pilot study - NA

CHU Sart-Tilman0 个研究点开始时间: 2006年9月28日最近更新: 2014年10月7日

适应症

试验速览

暂无简介。

•1. Hematological malignancies confirmed histologically and not rapidly progressing.
•2. Theoretical indication for a standard allo-transplant, but not feasible because:
•Age > 55 yrs; Unacceptable end organ performance; Patient’s refusal. OR
•Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant.
•3. Male or female; fertile female patients must use a reliable contraception method;
•4 Age 5 Informed consent given by patient or his/her guardian if of minor age.
•6 HLA-compatibility with HSC or cord blood donor as described in the protocol
•1 Related to the recipient (sibling, parent or child) or unrelated;
•2 Fulfills generally accepted criteria for allogeneic PBSC donation;
•3 Informed consent given by donor or his/her guardian if of minor age, as per donor center standard procedures.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1 Any condition not fulfilling inclusion criteria;
•2 HIV positive;
•3 Terminal organ failure, except for renal failure (dialysis acceptable);
•4 Uncontrolled infection, arrhythmia or hypertension;
•5 Previous radiation therapy precluding the use of 2 Gy TBI;
•6 HLA-identical donor.
•1 Any condition not fulfilling inclusion criteria;
•2 HIV positive;
•3 Unable to undergo leukapheresis because of poor vein access or other reasons.

发起方

CHU Sart-Tilman